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Summary
 
B cell malignancies arise with increased frequency in aging individuals and in patients with ge-
netic or acquired immunodeficiency (e.g., AIDS) or autoimmune diseases. The mechanisms of
lymphomagenesis in these individuals are poorly understood. In this report we investigated the
possibility that mutations at the 
 
Fas
 
 (
 
lpr
 
) and 
 
Fasl
 
 (
 
gld
 
) loci, which prevent Fas-mediated apop-
tosis and cause an early onset benign lymphoid hyperplasia and autoimmunity, also predispose
mice to malignant lymphomas later in life. Up to 6 mo of age, hyperplasia in
 
 lpr
 
 and 
 
gld
 
 mice
results from the predominant accumulation of polyclonal T cell subsets and smaller numbers of
polyclonal B cells and plasma cells. Here, we examined C3H-
 
lpr
 
, C3H-
 
gld
 
, and BALB-
 
gld
 
 mice
6–15 mo of age for the emergence of clonal T and B cell populations and found that a signifi-
cant proportion of aging mice exclusively developed B cell malignancies with many of the hall-
marks of immunodeficiency-associated B lymphomas. By 1 yr of age, 
 
z
 
60% of BALB-
 
gld
 
 and
30% of C3H-
 
gld
 
 mice had monoclonal B cell populations that grew and metastasized in 
 
scid 
 
re-
cipients but in most cases were rejected by immunocompetent mice. The tumors developed in
a milieu greatly enriched for plasma cells, CD23
 
2
 
 B cells and immunodeficient memory T cells
and variably depleted of B220
 
1
 
 DN T cells. Growth factor–independent cell lines were estab-
lished from five of the tumors. The majority of the tumors were CD23
 
2
 
 and IgH isotype
switched and a high proportion was CD5
 
1
 
 and dull Mac-1
 
1
 
. Considering their Ig secretion
and morphology in vivo, most tumors were classified as malignant plasmacytoid lymphomas.
The delayed development of the 
 
gld
 
 tumors indicated that genetic defects in addition to the
 
Fas
 
/
 
Fasl
 
 mutations were necessary for malignant transformation. Interestingly, none of the tu-
mors showed changes in the genomic organization of 
 
c-Myc
 
 but many had one or more somat-
ically-acquired MuLV proviral integrations that were transmitted in 
 
scid 
 
passages and cell lines.
Therefore, insertional mutagenesis may be a mechanism for transformation in 
 
gld
 
 B cells. Our
panel of in vivo passaged and in vitro adapted 
 
gld 
 
lymphomas will be a valuable tool for the fu-
ture identification of genetic abnormalities associated with B cell transformation in aging and
autoimmune mice.
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T
 
he recessive mutant genes, 
 
lpr 
 
and 
 
gld
 
, map to the 
 
Fas
 
and 
 
Fasl
 
 (ligand)
 
 
 
loci, respectively (1, 2). In normal
mice, 
 
Fas 
 
encodes a 45-kD cell surface receptor (Fas/
CD95/APO-1) belonging to the TNF/NGF receptor fam-
ily and 
 
Fasl 
 
encodes a 40-kD type II membrane protein,
FasL, homologous to members of the TNF family (1–5). In
receptive cells, the aggregation of Fas receptors by FasL or
anti-Fas mAb leads to the induction of cell death by apop-
tosis (6–8). Mice bearing the 
 
lpr 
 
mutation have a defect in
the expression of Fas caused by the insertion of a retroviral
transposon into the second intron of 
 
Fas
 
 that prevents nor-
mal transcription of the gene (1, 3). In 
 
gld
 
 mice, a point
mutation in the COOH-terminal region of 
 
Fasl 
 
results in
the expression of a non-functional form of FasL on the cell
surface (2, 4). Defective interactions between Fas and FasL
in mice homozygous for 
 
lpr
 
 or 
 
gld
 
 lead to indistinguishable,
progressive diseases typified by profound lymphadenopa-
thy, splenomegaly, high titers of circulating autoantibodies,
hypergammaglobulinemia, strain-dependent systemic au-
toimmune disease and premature death (reviewed in refer-
ence 9). Recently, there have been several reports of pedi-
atric patients with a variety of genetic mutations at the 
 
FAS
 
locus and a spectrum of immune abnormalities closely re-
sembling those of 
 
lpr
 
 and 
 
gld
 
 mice (10–14). The consistency
of the immunologic defects associated with 
 
Fas
 
 mutations
suggests a universal role for the Fas-associated cell deletion
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pathway in regulating lymphocyte survival and in prevent-
ing the accumulation of autoreactive B cells.
Between 1 and 6 mo of age, the spleens and lymph
nodes of 
 
lpr
 
 and 
 
gld 
 
mice undergo progressive enlargement
associated with the accumulation of two functionally unre-
sponsive B220
 
1
 
 T cell subsets not detected in normal mice.
Lymphadenopathy results predominantly from the selective
amassing of non-transformed B220
 
1
 
CD4
 
2
 
CD8
 
2
 
 double
negative (B220
 
1
 
DN)
 
1
 
 T cells (9, 15). The majority of these
cells are derived from CD8
 
1
 
 precursors selected in the thy-
mus on MHC class I Ag (16–19). The other B220
 
1
 
 T cell
subset is a minor one that expresses low levels of CD4 and
arises independently of MHC class I expression (16–20). As
the B220
 
1
 
 T cells accumulate, they dilute conventional
CD4
 
1
 
 and CD8
 
1
 
 T cells and B cells and disrupt the normal
architecture of the spleen and LN. Although normal T and
B lymphocytes are reduced by proportion, their total num-
bers in LN are increased approximately 10-fold (21, 22).
The expanded CD4
 
1
 
 and CD8
 
1
 
 T cell populations in 4–6-
mo-old
 
 lpr
 
 and 
 
gld
 
 mice are greatly enriched for memory-
like cells (9, 20–23). Similarly, the B cell population is en-
riched for cells with the phenotype of chronically activated
B cells and for Ig-secreting cells (9, 24). The skewing of the
T and B cell populations towards primed and activated cells
is consistent with the demonstrated role of Fas-mediated
apoptosis in regulating the survival of Ag-activated T cells
and autoreactive B cells (25–29). For C3H-
 
gld
 
, C3H-
 
lpr
 
and BALB-
 
gld
 
 mice whose median lifespans are 
 
z
 
12 mo,
lymphoproliferative disease persists until death but the cel-
lular composition of the lymphoid tissues in aging mice has
not been extensively studied.
Although defective Fas–FasL interactions in 
 
lpr 
 
and 
 
gld
 
mice lead to the accumulation of massive numbers of lym-
phocytes, there have been no reports of malignant T or B
lineage tumors arising in these mice. In unpublished studies
involving the transfer of spleen cells from BALB-
 
gld
 
 mice
with advanced disease into immunodeficient CB.17-
 
scid
 
mice, we observed that a significant number of recipients
developed malignant B cell lymphomas of donor origin.
To further investigate the possibility that 
 
gld 
 
mice sponta-
neously develop lymphomas that are masked by the preex-
isting lymphoproliferative disease, we surveyed groups of
C3H-
 
gld
 
 and BALB-
 
gld
 
 mice of various ages for evidence
of clonal, transformed lymphoid populations. These studies
revealed that by 1 yr of age, 28% of C3H-
 
gld 
 
mice and 57%
of BALB-
 
gld
 
 mice had monoclonal outgrowths of B cells in
spleen and LN. After transfer into 
 
scid
 
 recipients, the major-
ity of these clonal B cell populations gave rise to metastatic
plasmacytoid tumors. These findings provide evidence that
in addition to limiting the accumulation of polyclonally ac-
tivated and autoreactive lymphocytes, normal Fas–FasL in-
teractions also prevent the development of B cell neo-
plasms.
 
Materials and Methods
 
Mice.
 
All mice were bred and maintained at PerImmune,
(Rockville, MD; National Cancer Institute contract NOI CB-
710-85). C3H-
 
lpr/lpr
 
 (C3H-
 
lpr
 
) and C3H-
 
gld/gld
 
 (C3H-
 
gld
 
)
mice were bred from breeding pairs obtained from The Jackson
Laboratory (Bar Harbor, ME). BALB/c-
 
gld/gld
 
 (BALB-
 
gld
 
) mice
were bred in our colonies from C3H-
 
gld
 
 mice backcrossed for 15
generations to BALB/cAnPt mice. C3H-
 
scid/scid
 
 mice breeding
pairs were obtained from Sprague Dawley (San Diego, CA) and
C.B-17-
 
scid/scid
 
 breeding pairs were the gift of Dr. D. Hilbert
(NCI, NIH, Bethesda MD). For tumor transfer studies, 
 
scid 
 
recip-
ients were injected i.p. with 1 to 2 
 
3
 
 10
 
7
 
 donor spleen or LN
cells. Tumor-bearing mice were palpated weekly and killed 2–6
wk post-transplant before they became moribund.
 
Characterization of Tumors.
 
Lymphoid tissues from mice bear-
ing primary tumors or from 
 
scid
 
 mice with tumor transplants were
processed for histology, FACS
 
Ò
 
 analysis, and in vitro culture. Tu-
mor cells were viably frozen and cell pellets were snap frozen for
DNA and RNA extraction. Cell lines were established from
spleen or LN cells from
 
 scid
 
 mice with tumor transplants. The
lines were maintained in complete RPMI 1640 with 10% fetal
bovine serum.
 
DNA Analyses.
 
High MW DNA was isolated, digested with
EcoRI, HindIII, HpaI or PvuII (Boehringer Mannheim, India-
napolis, IN), separated on 0.7% agarose gels and blotted onto
Nytran membranes (Schleicher & Schuell, Keene, NH) using es-
tablished techniques. Probes used included J
 
11
 
, a 1.96-kb BamHI–
EcoRI fragment of the BALB/c germline J
 
H 
 
region (30); IVS, a
1.1-kb EcoRI–Xba fragment of the BALB/c germline C
 
k 
 
region
(31); CT
 
b
 
, a 618 bp BamHI–EcoRI fragment containing the J and
C regions of 86TI (32), a cDNA clone coding for the 
 
b
 
-chain of
the T cell receptor; pEco, a 400-bp SmaI fragment derived from
an AKR ecotropic virus 
 
env 
 
gene (33); and pvt, a 1.4-kb EcoRI
fragment of the germline 
 
Pvt1 
 
(34). The 
 
c-Myc
 
 probe was a 1.3-
kb fragment containing exon 2 and exon 3 (gift from Dr. K.
Huppi, NCI, NIH, Bethesda, MD). The probes were 
 
32
 
P-labeled
by nick translation (Lofstrand, Rockville, MD). Washings of
Southern blots were done to a final stringency of 0.13 SSC, 0.5%
SDS at 658C.
FACSÒ Analyses. Single cell suspensions of spleen and LN
were prepared, blocked with anti-CD32 mAb, and stained as de-
scribed previously (15). Analyses were performed on a FACScanÒ
(Becton Dickinson, Sunnyvale, CA). Dead cells were eliminated
from the analysis by propidium iodide gating. Abs used for staining
included various combinations of Tri-color (TC)-labeled anti-
CD45(B220), anti-CD8 (Caltag, San Francisco, CA), PE-labeled
mAb specific for CD4, IgL k, IgL l, CD45(B220), CD8, CD32,
CD19, and CD95(Fas) and FITC-labeled mAb specific for TCR-
a/b, ThB, CD11b (Mac-1), CD23, CD80 (B7-1), CD86 (B7-2),
6C3 (Ly-6C), CD43, I-Ak, I-Ad, CD5, IgM, IgG1, IgG2b,
IgG2a, and IgG3 (PharMingen, San Diego, CA).
Preparation of Tissues for Histology. Tissues were fixed in mod-
ified Tellyesniczky’s solution and processed at American Histolab,
Gaithersburg, MD.
Quantitation of Anti-ds-DNA Autoantibodies in Sera. 96-well flat
bottomed microtiter plates were coated with 10 mg/ml methylated
BSA (Sigma Chemical Co., St. Louis, MO) in carbonate buffer
(pH 9.6) overnight at 48C. After washing with PBS/0.05% Tween
20, the plates were incubated with 10 mg/ml calf thymus DNA in
carbonate buffer overnight at 48C. The plates were blocked with
dilution buffer containing 2% PEG 8000, 1% gelatine, 0.05%
Tween 20, 1% BSA in PBS for 30 min. at 378C. Serum samples
1Abbreviations used in this paper: ALPS, autoimmune lymphoproliferative
syndrome; DN, double negative; IAL, immunodeficiency-associated lym-
phomas; MAIDS, mouse AIDS; RT, room temperature.1827 Davidson et al.
were diluted twofold starting at 1:500 in diluting buffer, added to
the plates, and incubated for 2 h at 378C. Anti-DNA Ab binding
was detected with biotinylated anti-mouse IgG (Southern Bio-
technology) and POD-labeled streptavidin using ABTS as the
substrate.
Quantitation of Serum Ig Levels. Levels of IgM, IgG1, IgG2a,
IgG2b, IgG3, and IgA in sera were determined by ELISA. ELISA
plates were coated overnight at 48C with 50 ml of goat antibodies
specific for mouse IgM, IgA, IgG2a, IgG2b, and IgG3 diluted to
5 mg/ml or 50 mg/ml (IgG3) in carbonate buffer (KPL, Gaithers-
burg, MD). After washing the plates were blocked with 200 ml of
SuperBlock (Pierce Chemical Co., Rockford, IL) for 20 min  at
room temperature (RT). Ig standards and serial dilutions of
mouse sera (50 ml) in blocking buffer were added and the plates
were incubated for 2 h at RT. After washing the plates with PBS-
Tween, 100 ml of the following detecting mAb labeled directly
with HRP or AKP were added to the appropriate wells. Anti-
IgG2a (R19-15) 1:1,000, anti-IgG2b (R12-13) 1:2,000, anti-
IgG3 (R40-82) 1:100, anti-IgA (R6-60.2) 1:1,000, and anti-IgM
(R5-140) 1:1,000 (PharMingen). The plates were incubated for
1.5 h at RT then washed with PBS-Tween. The HRP or AKP
substrates (KPL, Gaithersburg, MD) were added, the reaction was
stopped and the plates were read.
Results
Evidence for the Outgrowth of Clonal B Cell Populations in
11–15-mo-old BALB-gld and C3H-gld Mice. To further in-
vestigate the possibility that defects in the Fas–FasL-mediated
cell death pathway may predispose mice to the development
of B cell lymphomas, we surveyed groups of 4–8-mo-old
and 9–16-mo-old BALB-gld and C3H-gld mice for tumor
incidence. All mice had advanced lymphoproliferative dis-
ease and the majority were not moribund at the time of
death. For each mouse, lymphoid and nonlymphoid tissues
were processed for histologic analysis, spleen, and lymph
node were analyzed by FACSÒ for the distribution of lym-
phocyte subsets, DNA was extracted from spleen and LN
and examined for evidence of clonal expansion of cells
with rearranged IgH, IgL, or TCR genes, and fresh or via-
bly frozen lymphoid cell suspensions were transferred into
immunodeficient scid recipients. Similar analyses also were
performed on groups of 25 BALB1/1 and C3H1/1 control
mice 10–25 mo of age. The results of Southern blot analy-
ses of DNA for IgH and IgL gene rearrangements are sum-
marized in Table 1. For both BALB-gld and C3H-gld mice,
there is strong evidence for an age-related accumulation of
cells with clonal IgH and IgL rearrangements in both
spleen and LN. Among DNA samples from a total of 46
9–15-mo-old BALB-gld mice, 39 (85%) had one or more
prominent rearranged IgH and IgL bands, three (6%) had
rearranged IgH bands only, and four (9%) had no detect-
able rearranged bands.
Of the 39 samples with clonal IgH and IgL rearrange-
ments, 26 (67%) had between one to three prominent rear-
ranged IgH and IgL bands common to spleen and LN sug-
gesting the selective outgrowth of one or two B cell clones.
Fig. 1 shows typical examples of members of this group.
Except for sample 540, only data for LN DNA is shown,
but in each case, identical bands also were present in
spleen. The remaining thirteen samples had four or more
rearranged IgH and IgL bands suggesting the accumulation
of oligoclonal B cell populations (Table 1). Potential mono-
clonal/biclonal B cell populations also were detected in the
spleens of 2/12 4–8-mo-old BALB-gld mice (Table 1).
Among 68 11–15-mo-old C3H-gld mice examined, 28%
(19/68) had outgrowths of monoclonal/biclonal B cell
populations in spleen and LN, 15% (10/68) had oligoclonal
B cell populations and the remainder (57%) had no detect-
able clonal outgrowths (Table 1). Typical examples of
C3H-gld mice with potential monoclonal/biclonal B cell
populations in spleen and LN are shown in Fig. 2. In con-
trast to the 4–8-mo-old BALB-gld mice, no clonally ex-
panded B cell populations were detected in the spleens or
LNs of 4–8-mo-old C3H-gld mice (Table 1).
The accumulation of clonal B cell populations with age
is not restricted to gld mice. The incidence of monoclonal/
biclonal and oligoclonal B cell populations in the spleen
and LN of 25 11–15-mo-old C3H-lpr mice paralleled that
for age-matched C3H-gld mice (Table 1). In contrast, no
clonal outgrowths of cells with IgH or IgL rearrangements
were detected in the spleens of 12 to 15 mo old control
C3H1/1 or BALB1/1 mice by Southern blot analyses and
there was no histologic evidence of tumor development in
these mice (Fig. 3 and data not shown). In spite of the mas-
sive accumulation of T cells in lpr and gld mice, populations
of cells with clonal rearrangements of TCR-b genes were not
detected in the spleen or LN at any age (data not shown).
Monoclonal B Cell Populations from BALB-gld and C3H-gld
Mice Grow and Metastasize in scid Recipients. To determine
Table 1. Outgrowth of Clonal B Cell Populations in C3H-lpr, 
C3H-gld, and BALB-gld Mice
Strain Age Range
Number
of mice
IgH and IgL gene
rearrangements
Mono- or
biclonal* Oligoclonal‡ None§
mo
BALB-gld 4–8 12 2 3 7
9–15 46i 26 13 4
BALB1/1 10–21 22 0 0 22
C3H-gld 4–8 9 0 0 9
11–15 68 19 10 39
C3H-lpr 11–15 25 8 4 14
C3H1/1 11–15 25 0 0 25
*Spleen and LN cell DNA with #4 prominent rearranged clonal IgH
and IgL bands.
‡Spleen and LN cell DNA with .4 rearranged IgH and IgL bands.
§No detectable clonal rearrangements.
iThree mice had rearranged IgH bands without detectable rearranged
IgL bands.1828 B Cell Lymphomagenesis in gld Homozygous Mice
if the monoclonal/biclonal B cell populations accumulating
with age in the BALB-gld and C3H-gld mice were trans-
plantable, fresh or viably frozen spleen or LN cells were in-
jected intraperitoneally into histocompatible immunodefi-
cient scid recipients. Of 23 suspected tumors inoculated,
twenty gave rise to metastatic monoclonal B lineage tumors
3–8 wk after inoculation. As shown in Figs. 1 and 2, each
tumor transplant had identically rearranged IgH and IgL
bands to the clonal B cell populations in the primary inoc-
ulum. In one C3H-gld mouse, 217, at least two B cell
clones were present originally but only one grew out con-
sistently in scid mice (Fig. 2). The tumors showed some
variations in their growth patterns in adoptive transfers.
The C3H-gld tumor 355 grew very aggressively in all lym-
phoid organs. All of the other tumors grew rapidly in the
spleen, mesentery, mediastinal and mesenteric LN and
more slowly in peripheral LN. The majority of the tumors
metastasized to the liver, lungs, and kidneys. Some tumors,
(e.g., C3H-gld tumors 142, 217, and 221 and the BALB-gld
tumor 540) also grew in the ovaries and uterus. Only the
C3H-gld tumors 217 and 205 induced copious production
of ascites. In contrast, there was no selective outgrowth of
B cells in scid mice injected with spleen or LN cells from gld
or 1/1 mice with no evidence of clonal B cell populations
(data not shown).
The C3H-gld tumors 142, 205, 217, 355, and 362 were
injected i.p. or s.c. into 6–8-wk-old C3H1/1, -gld, and -lpr
recipients and the BALB-gld tumors 311 and 208 were in-
jected i.p. or s.c. into 6–8-wk-old BALB1/1 and -gld mice
to determine if they would grow in immunocompetent
mice or have a growth advantage in gld recipients. The cells
used for injection were grown in scid mice and were highly
enriched for tumor cells. Tumor growth was assessed histo-
logically, by FACSÒ, and by Southern blot analysis. Tumor
355 grew very aggressively in the peritoneal cavity, spleen,
and peripheral LN in all three groups of recipients and
killed the mice within 2 weeks of inoculation. Tumor 142
grew in the ovaries of 1/5 C3H-gld recipients but was not
detected in C3H-lpr or C3H1/1 mice 2 mo after injection.
None of the remaining tumors grew in, or were recover-
able from, any of the recipients 2–6 mo after inoculation.
To determine if the tumors had a growth advantage in
older mice with advanced lymphoproliferative disease, tu-
mors 217 and 205 were injected i.p. into groups of 7 mo
Figure 1. Evidence for the development of monoclonal/biclonal B lin-
eage tumors in aging BALB-gld mice. Top and bottom panels show
Southern blot analyses of genomic DNA isolated from the LN of repre-
sentative 8 to 12 mo old BALB-gld mice bearing primary tumors, and
from the LN of C.B-17-scid mice bearing the corresponding transplanted
tumor (primary transplant). Data also are shown for splenic DNA from
the primary 540 tumor and for DNA from the 311 cell line. In the top
panel, DNA was digested with EcoRI and examined for rearrangement of
the IgH locus with the pJ11 probe. In the bottom panel, DNA was di-
gested with HindIII and examined for rearrangement of the IgL locus
with the IVS probe. GL, indicates the position of the unrearranged germ-
line IgH and IgL bands in BALB-gld kidney DNA (lane 19).
Figure 2. Evidence for the development of monoclonal/biclonal B lin-
eage tumors in aging C3H-gld mice. Panels show Southern blot analyses
of genomic DNA for IgH (top) and IgL (bottom) gene rearrangements (see
Fig. 1 legend for details). DNA samples isolated from the spleen and LN
of C3H-gld bearing primary tumors, from the LN of C3H-scid mice bear-
ing primary tumor transplants and from cell lines are compared. GL indi-
cates the position of the germline IgH and IgL bands.1829 Davidson et al.
old lpr mice and the mice were killed 2 mo later. No tumor
growth was detected in any of the recipients (data not
shown).
Age-related Changes in the Cellular Composition of Lymphoid
Organs in gld Mice. The BALB-gld mice used in this study
have not been described previously. These mice developed
progressive lymphoproliferative disease closely resembling
that of C3H-gld mice in terms of time of onset, severity,
and pathology. At 4–5 mo of age, when lymphadenopathy
and splenomegaly were well established and comparable in
both strains, some consistent but minor strain-related dif-
ferences were observed in the proportions of the various T
cell subsets. As shown in Fig. 4, B2201 DN T cells pre-
dominated in the LN of both strains of mice at 4–5 mo of
age but the BALB-gld mice had lower proportions of this
subset and higher proportions of CD41 T cells, CD41
B2201 T cells and CD81 T cells than the C3H-gld mice.
Between 6 mo and z1 yr of age, a previously unreported
redistribution of lymphocyte subsets occurred in the LN of
both BALB-gld and C3H-gld mice. This was more appar-
ent in the C3H-gld mice and was characterized by a selec-
tive decrease in the proportions of B2201 DN T cells from
79.5 6 1.4% to 35.1 6 2.1%, and a three- to fourfold in-
crease in the proportions of CD41 T cells, CD81 T cells
and B cells (Fig. 4). A small 1.6-fold increase in the propor-
tion of CD41B2201 T cells also was observed (Fig. 4).
Spleens from aging C3H-gld mice and LN and spleens from
aging BALB-gld mice showed a similar pattern of changes
in the distribution of T cell subsets (Fig. 4 and data not
shown). These changes in cellular composition were not
Figure 3. Clonal B cell outgrowths are not detected in the spleens of 12–
15-mo-old Balb/c1/1 mice. Panels show Southern blot analyses of ge-
nomic DNA for IgH (top) and IgL (bottom) gene rearrangements. DNA
was isolated from the spleens of 12–15-mo-old Balb/c1/1 (lanes 1–11) or
from Balb/c1/1 kidney (lane 12). GL indicates the position of the germ-
line IgH and IgL bands. Data are representative of 25 mice analyzed.
Figure 4. Age-related changes in the distribution of T and B cell sub-
sets in the LN of C3H-gld and BALB-gld mice. The percentage of each
lymphocyte subset (identified in top right hand corner) was determined
by 3-color FACSÒ analysis of LN cells from individual BALB-gld and
C3H-gld mice aged 4–5 mo, 7–10 mo, and .11 mo. Data is shown for all
mice .11 mo and mice .11 mo with tumors. The proportions of B2201
DN T cells were determined by staining cells with PE-labeled anti-CD4
and anti-CD8, Tri-color-conjugated anti-CD45(B220), and FITC-labeled
anti-TCR-a/b. The histograms represent the mean plus SE of values for
11 to 68 C3H-gld mice (top six panels) and 11–23 BALB-gld mice (bot-
tom six panels).1830 B Cell Lymphomagenesis in gld Homozygous Mice
accompanied by a reduction in LN or spleen size or cellu-
larity and did not correlate with the development of B lin-
eage tumors (Fig. 4 and data not shown). Among the B
cells, there was an age-related increase in the proportions
and numbers of kappa1B2201CD191ThB1CD52CD232
cells. By z1 yr of age, the majority of the B cells in LN and
spleen were of this phenotype (Fig. 5). Among these cells, a
subset also expressed low to intermediate levels of Mac-1
(Figs. 4 and 5). In LN, the Mac-11 subset represented
fewer than 0.5% of cells at 4–5 mo of age and by z1 yr of
age had increased to 2.7 6 0.9% in C3H-gld and 7.5 6
1.8% in BALB-gld mice. Between 4 and z12 mo of age,
the proportions of Mac-11 B cells in spleen increased from
1.6 6 0.3% to 5.0 6 0.4% for C3H-gld mice and from 2.6
6 0.5% to 9.8 6 1.4% for BALB-gld mice. In contrast, this
subset represented fewer than 3% of the cells in the spleens
of 11–15-mo-old C3H1/1 and BALB1/1 mice (data not
shown). Although the accumulation of CD232 Mac-11 B
cells was greatest in tumor-bearing mice, animals lacking
tumors also had significantly increased proportions of these
cells (Figs. 4 and 5 and data not shown).
Comparisons of the Phenotypes of the Primary Tumors and
scid-propagated Tumors. Among the tumor bearing mice,
Ig1 B cells rarely exceeded 10–20% of the total population
in LN and spleen and the tumor population was not readily
identified by a unique phenotype or selective increase in
size. Therefore, accurate phenotyping and morphologic
classification of the tumors was dependent on their selec-
tive outgrowth in scid transplants. This is illustrated in Fig.
6 for tumor 217 which is representative of the majority of
the tumors isolated. The LN of the mouse bearing the pri-
mary tumor had 29% CD81 T cells, 36% CD41B2202 T
cells, 11% CD41B2201T cells, 2% B2201DN T cells and
10% k1B2201ThB1 B cells (Fig. 6 and data not shown).
Approximately 60% of the B cells in LN and spleen ex-
pressed low levels of Mac-1. Transfer of these LN cells
into scid mice resulted in an aggressive outgrowth of do-
nor cells in the spleen and mesenteric LN, cellular infiltra-
tion of nonlymphoid organs, and the production of as-
cites. In a typical recipient, 40% of the cells in LN were
kappa1IgG31B2201ThB1Ia1CD51 CD801CD861Fas1 B
cells and 38% of these expressed low levels of Mac-1 (Fig. 6
and data not shown). The whole B cell population also re-
acted weakly with anti-CD4 mAb (Fig. 6). B cells with a
similar phenotype represented 64% of the spleen cells (data
not shown). With a few exceptions, the primary scid trans-
plants of the remaining C3H-gld and BALB-gld tumors had
phenotypes closely resembling 217. All of the tumors ex-
pressed intermediate to high levels of B220, Ia, CD16/32,
Figure 5. Age-related accumulation of B2201CD191ThB1kappa1
CD232 B cells in gld mice. LN cells from a 12-mo-old BALB-gld mouse
with no detectable tumor were stained with the reagents indicated. Values
inside the quadrants represent the proportions of positive cells. Two thirds
of the CD191 B cells were Mac-12 and one third expressed low levels of
Mac-1.
Figure 6. Phenotype of the C3H-gld tumor, 217 in vivo. Panels on the
right hand side show FACSÒ data for LN cells from the mouse bearing
the primary tumor 217. The adjacent panels show corresponding data for
LN cells from C3H-scid mice bearing the primary (center) and secondary
(right) 217 transplants. Cells were stained with the reagents indicated and
analyzed on the FACScanÒ. The values inside each quadrant represent the
percentage of reactive cells.1831 Davidson et al.
CD19, CD80, and CD86 and levels of ThB ranging from
low to high. Only 355 was Fas2. Most of the tumors were
CD232 and expressed low to intermediate levels of CD5
and low levels of Mac-1. Five tumors, 142, 205, 355, 362,
and 311, were consistently sIg2 and the remainder had low
to intermediate levels of IgH and IgL chains. With the ex-
ception of 142 which was l1, all sIg1 tumors expressed
kappa L chains. A variety of IgH isotypes were expressed
including IgM, IgG1, IgG2a, IgG3, and IgA (Table 2). Sera
from the majority of the scid mice transplanted with Ig1
C3H-gld and BALB-gld tumors had high titers of Ig of the
same isotype expressed on the tumor (Table 2). The surface
Ig2 tumors growing in scid mice also secreted Ig of a single
isotype (Table 2). Notably, none of the sera reacted with
ds-DNA (Table 2). In many instances, the primary tumors
also appeared to be secreting Ig as one or two gamma
spikes were detected in electrophoreses of sera from 66%
(19/29) of tumor-bearing mice (data not shown). Histolog-
ically, the tumor populations in the primary scid transfers
were a mixture of immunoblasts, plasmacytoid cells and
plasma cells.
Surprisingly, 40% of the LN cells in the primary scid
transplant of 217 were T cells (28% TCR-a/b1CD81T
cells and 12% TCR-a/b1CD41 T cells) and significantly
more T cells were recovered than were present in the orig-
inal inoculum. The proliferation of T cells in the first scid
transfer was observed with many of the C3H-gld and
BALB-gld tumors and was not always skewed towards
CD81 T cells. Analyses of TCR-b chain gene rearrange-
ments showed no evidence of clonality among the T cell
populations in any of the scid recipients (data not shown).
Of note, there was no significant outgrowth of B2201 DN
T cells or B2201CD41 T cells in any of the scid mice inoc-
ulated with tumor-bearing populations.
In secondary scid transfers with LN cells from the pri-
mary scid recipients, clonal descendants of the 217 tumor
cells predominated and T cells represented fewer than 3%
of the cells (Fig. 6). The tumor population was enriched
further for plasmacytoid cells and plasma cells as illustrated
by high titers of serum IgG3 and changes in phenotype
and morphology. The majority of the cells remained
IgG31CD451CD51ThB1Ia1CD801CD861Fas1CD191
dull CD41 and dull Mac-11 and a significant proportion
downregulated their expression of surface Ig and switched
from CD45(B220) expression to a lower MW CD45 iso-
form (Fig. 6 and data not shown). This skewing of the tu-
mor population towards more differentiated plasmacytoid
cells and plasma cells in secondary and subsequent scid
transfers was a hallmark of the majority of the tumors aris-
ing in C3H-gld and BALB-gld mice.
Establishment and Phenotype of Tumor Cell Lines. Among
the 19 tumors that grew in scid recipients, 5 (142, 205,
217, 355, and 311) have been adapted successfully to cul-
ture. All of the tumors propagated in scid mice survived for
at least 2–3 wk in culture but were difficult to maintain
long-term. Only 355 grew aggressively and independently
from the beginning. Initially, tumors 142, 205, 217, and
311 were highly dependent on adherent stromal cell popu-
lations for their survival and these could not be substituted
with IL-6. The tumor cells adhered tightly to the stromal
cells and had to be trypsinized to be passaged. Subse-
quently, stromal cell–independent sublines were established
for all four lines. These lines grow both in large clusters and
as weakly adherent monolayers. Analyses of IgH and IgL
gene rearrangements confirmed that each cell line was
clonally related to the scid-transfer tumor from which it was
established (Figs. 1 and 2). All of the lines grew vigorously
in scid mice (data not shown). In general, the cell lines were
phenotypically similar to the scid-propagated cells from
which they were derived but showed changes in the level
of expression of some antigens. For example, there was
downregulation of the expression of ThB and CD45(B220)
on the 217 line and of ThB, Fas, CD80, and CD86 on the
311 line (Fig. 7). Although T cell proliferation was often
observed in the primary scid passages of the tumors, none of
the cell lines induced the proliferation of 1/1 or gld T
cells in syngeneic mixed lymphocyte cultures (data not
shown).
Histopathologic Changes in Aging C3H-gld and BALB-gld
Mice. The first organs to be affected in C3H-gld and
BALB-gld mice were the lymph nodes, particularly the
Table 2. Tumor Surface and Secreted Ig Isotypes
Tumor Surface Ig* Secreted Ig‡
Myc/Pvt 1
rearrangements§
C3H-gld
142 IgG2a IgG2a NDi
205 Null IgG2a ND
217 IgG3 IgG3 ND
221 Null IgA ND
223 IgG3 IgG3 ND
355 Null IgG2a ND
362 Null IgG3 ND
BALB-gld
208 IgG1 IgG1 ND
311 Null IgG3 ND
329 IgM IgM ND
421 IgM IgM ND
424 IgA IgA ND
425 IgG2a IgG2a ND
426 IgA IgA ND
536 IgA IgA ND
540 IgG2a IgG2a ND
*Surface Ig expression on scid-passaged tumor cells determined by
FACSÒ analysis.
‡Isotype of secreted Ig in sera from tumor-bearing scid mice deter-
mined by ELISA assay.
§Rearrangement of Myc and Pvt1 loci determined by Southern blot
analysis of genomic DNA from scid-passaged tumors.
iND, not detected. Rearrangements of Myc or Pvt1 were not detected.1832 B Cell Lymphomagenesis in gld Homozygous Mice
subcutaneous ones. Normal LN architecture was lost as the
B2201 DN T cells selectively accumulated. By z4 mo of
age, sheets of homogeneous medium-sized DN T cells
with characteristically stippled chromatin totally replaced
the cortex and expanded the medullary cords so that the si-
nusoids were effaced (Fig. 8 A). At the same time, the
splenic white pulp became greatly enlarged and cells mor-
phologically resembling the B2201 DN T cells occupied
both the periarteriolar sheath and the mantle zone (data not
shown). In both the LN and spleen, plasmacytoid cells
were present in variable numbers but they represented a
small minority of cells. In the lung, periarteriolar cuffing by
lymphoid cells was moderately advanced, but the kidneys
and liver were unaffected at this time (data not shown).
Beyond 6 mo of age, the LN and spleen underwent fur-
ther changes in cellular composition and cellular infiltration
of nonlymphoid tissues was more widespread. These changes
occurred in both tumor-bearing mice and mice without
apparent tumors. In LN and spleen, the cells became pro-
gressively less densely packed and the stromal elements
were more apparent. The homogeneous DN T cell popu-
lation was replaced increasingly by small lymphocytes, im-
munoblasts, plasmacytoid cells, plasmablasts, and plasma
cells. Consistent with a previous report by Jacobson et al.
(35), the plasma cells in spleen characteristically accumu-
lated around the central arteriole in the periarteriolar lym-
phoid sheaths. Infiltration, mainly by plasmacytoid cells,
became increasingly severe in the lungs, portal areas of the
liver, and renal medulla. Fig. 8 B shows typical cellular
changes and plasma cell infiltrates in the LN of a 12-mo-
old C3H-gld mouse with no detectable tumor.
The increased presence of the activated B cell popula-
tions and plasma cells, together with the underlying T cell
accumulation greatly complicated the morphologic classifi-
cation of the primary tumors. This difficulty is illustrated
well by the prototypic tumor 217. For this tumor, there
was moderate splenic and hepatic, and more severe renal
infiltration. However, as shown in Fig. 8 C and D, the cells
Figure 7. Cell surface marker expression on in
vitro-propagated cell lines established from the
C3H-gld tumor, 217, and the BALB-gld tumor,
311. Cells were stained with the antibodies indi-
cated (heavy lines) or with a non-reactive FITC- or
PE-conjugated control Ab (light lines) as described
in Materials and Methods.1833 Davidson et al.
were morphologically heterogeneous making it difficult to
identify the tumor population. In the first and all subse-
quent passages of 217 in scid mice, there was extensive tu-
mor infiltration of the lymphoid organs, lungs, liver, mes-
entery, perirenal fat, ovaries, and uterus and to a lesser
extent kidneys. Fig. 8 E illustrates the intrauterine infiltra-
tion in the first scid passage. In the primary passage of 217
and most of the other C3H-gld and BALB-gld tumors, the
infiltrating cells were a mixture of donor T cells and tumor
cells but in the subsequent passages the infiltrates were
composed almost exclusively of monoclonal tumor cells
(Fig. 5 and data not shown). In all passages, the 217 tumor
population was morphologically heterogeneous and in-
cluded immunoblasts, plasmablasts and plasma cells in vary-
ing proportions (Fig. 8 F). All of the BALB-gld and most of
the C3H-gld tumors closely resembled 217 in their patterns
of growth and morphology. The exceptions among the
C3H-gld tumors were 355, 205, and 142. Whereas these
clearly were mature B cells by phenotype and Ig secretion,
they were less differentiated morphologically. In summary,
even though morphologic identification of the primary
C3H-gld and BALB-gld tumors was difficult, their clonal
descendants that proliferated in scid recipients almost uni-
versally were skewed towards the late stages of B cell differ-
entiation and were classified as malignant plasmacytoid
lymphomas.
C3H-gld and BALB-gld Tumors Have Somatically Acquired,
Clonal MuLV Proviral Integrations. The transformation of
mature B lineage cells frequently involves multiple genetic
events including the dysregulated expression of cellular
protooncogenes. For example, plasmacytomagenesis often
is associated with dysregulated expression of c-Myc caused
by the translocation of this gene to the switch regions of
the IgH locus or by rearrangement of the Pvt1 locus (34,
36). Abnormal expression of oncogenes also can occur fol-
lowing the insertion of infectious endogenous retroviruses
into the genome (37). To determine the potential involve-
ment of either of these mechanisms in the development of
the gld tumors, DNA from the primary tumors, scid trans-
fers and cell lines was examined for evidence of c-Myc
translocation and proviral integrations. Rearrangement of
c-Myc was investigated by Southern blot analysis and PCR
analysis using primers specific for c-Myc and the m, a, g1,
and g2a switch regions. None of the C3H-gld or BALB-gld
primary tumors, transplants or cell lines showed evidence
Figure 8. Malignant and nonmalignant lymphoid infiltrates in the tis-
sues of aging gld mice. A illustrates the selective accumulation of DN T
cells with characteristically stippled chromatin in a section of LN from a
4-mo-old C3H-gld mouse (H&E, original magnification 6003). B shows
a typical example of the loss of the DN T cell population and the accu-
mulation of nonmalignant plasma cells in the LN of a tumor-free 12-mo-
old C3H-gld mouse (H&E, original magnification 6003). C and D show
the morphologic heterogeneity of the cellular infiltrates in the spleen (C,
original magnification 2003) and kidney (D, original magnification
1003) of the C3H-gld mouse bearing the primary 217 tumor. Panel E il-
lustrates the extensive infiltration of the uterus with malignant plasmacy-
toid cells and plasma cells and non-malignant T lymphocytes in a C3H-
scid mouse inoculated with the primary 217 tumor. F shows a LN section
from a C3H-scid mouse bearing the second passage of tumor 217 in
which the majority of the cells are monoclonal tumor cells (H&E, original
magnification 6003). The mixture of immunoblasts, plasmablasts and
plasma cells is typical of the morphologic heterogeneity associated with
the malignant plasmacytoid gld lymphomas.
Figure 9. Evidence for somatically-acquired clonal MuLV proviral in-
tegrations in C3H-gld tumors. Southern blot of genomic DNA from pri-
mary tumors, scid-passaged tumors and tumor cell lines digested with
PvuII and probed with a 32P-labeled ecotropic MuLV probe. DNA from
C3H-gld kidney shows the position of the single hybridizing germline
(GL) band present in normal C3H cells.1834 B Cell Lymphomagenesis in gld Homozygous Mice
of c-Myc translocation, or amplification or disruption of the
Pvt1 locus (data not shown).
Both C3H and BALB/c mice have single germline cop-
ies of endogenous infectious ecotropic MuLV (Figs. 9 and
10). In contrast, a high proportion of the C3H-gld and
BALB-gld tumors had somatically acquired MuLV proviral
integrations. As shown in Fig. 9, the transplantable C3H-gld
tumors 142, 205, 355, 221, 223, and 362 had between 2
and 13 viral integrations in the primary tumor. 217 was the
only primary tumor with no evidence of newly acquired
proviral integrations. A different pattern of viral integra-
tions was observed for the BALB-gld mice (Fig. 10).
Among 17 monoclonal transplantable tumors surveyed,
seven had newly acquired proviral integrations in both the
primary and scid-propagated populations (e.g., 425 and
540), seven had integrations in the transplanted but not the
primary tumor (e.g., 311 and 536), and three had no de-
tectable new integrations (e.g., 329). In general, the pri-
mary BALB-gld tumors had many fewer somatically acquired
proviral insertions than the C3H-gld tumors (Figs. 9 and
10). This difference is most likely explained by known dif-
ferences between BALB/c and C3H mice in the genetic
loci that regulate the spread of N-tropic ecotropic virus
with BALB/c mice being restrictive and C3H mice per-
missive (38). Most of the bands in the primary C3H-gld and
BALB-gld tumors also were present in the scid transplants
and in the in vitro cell lines indicating that the majority of
the proviral integrations are stable. In some cases new bands
arose in the scid transplants and the cell lines. This is partic-
ularly evident in the scid transplants of 217 and 536 and in
the 311 cell line (Figs. 9, 10). Although these new integra-
tions clearly are not involved in tumor induction, they may
be important for tumor progression or adaptation to cul-
ture. The great variation in the sizes of the viral bands indi-
cate that there are few common integration sites among the
tumors. It should be noted that somatically acquired eco-
tropic virus integrations were not detected in DNA from
young gld mice or tumor-free aged gld mice (data not
shown).
Discussion
This study was undertaken to examine the effects of the
life-long absence of a functional Fas–FasL-mediated cell
deletion pathway on spontaneous lymphomagenesis. We
showed that a mutant, nonfunctional FasL significantly ac-
celerated the onset and increased the incidence of lympho-
mas in C3H and BALB mice. The tumors developed in a
milieu greatly enriched for plasma cells, CD232 B cells and
memory-like CD41 and CD81 T cells and variably de-
pleted of B2201 DN T cells. The lymphomas were re-
stricted to the B cell lineage, were skewed towards the ter-
minal stages of B cell differentiation, were transplantable in
immunodeficient mice, and hence were classified as malig-
nant plasmacytoid lymphomas. The majority of the tumors
were CD232 and IgH isotype switched and a high propor-
tion were CD51 Mac-1 dull. None of the tumors showed
changes in the genomic organization of c-Myc.
The age-related accumulation of a putatively primed or
activated IgM1CD232CD52 B cell subset unrelated to
CD232 B-1a or B-1b cells has been reported previously for
MRL-lpr, B6-lpr, and B6-gld mice (24). Our studies show
that a similar B cell population accrues in aging C3H-gld
and BALB-gld mice, and that in these strains a subset of the
cells also express low levels of Mac-1. The accumulation of
CD232 cells in lpr and gld mice may be a consequence of
chronic B cell activation and/or increased longevity stem-
ming from the Fas–FasL defect. If the CD232 B cells are
long-lived, they may be at increased risk of transformation,
and in this regard resemble the naturally long-lived B-1a
and B-1b cells that give rise to lymphomas in aging NZB
mice (39). The development of gld tumors that phenotypi-
cally resembled isotype-switched CD232 B2 cells, CD232
CD51Mac-11 B-1a cells, and CD232CD52Mac-11 B-1b
cells implies that each of these B cell subsets may be suscep-
tible to transformation in gld mice.
There is compelling evidence that chronic inflammatory
diseases or infections resulting in persistent lymphoprolifer-
ation may be conditioning events in the development of B
cell malignancies (40–42). As one example, there is a strong
correlation between infection with Helicobacter pylori and
the development of B lineage gastric lymphomas (43, 44).
Although chronic infections are unlikely to be a driving
force in the development of tumors in Fas–FasL-deficient
mice, self antigens may be responsible for chronic B cell ac-
tivation. In support of this proposal, lymphoma-bearing
TCR-b/d-deficient lpr mice had high titers of circulating
anti-mouse IgG autoantibodies (45). In the present study, none
of the gld tumors secreted detectable levels of anti-dsDNA
autoantibodies, but a role for other autoantigens in pro-
moting chronic B cell stimulation has not been eliminated.
Figure 10. Somatically-acquired clonal MuLV proviral integrations in
BALB-gld tumors. Southern blot analysis of PvuII-digested genomic
DNA from BALB-gld primary tumors, scid transplants and the 311 cell
line. The blot was hybridized with a 32P-labeled ecotropic MuLV probe.
Control DNA samples from BALB-gld and C.B-17-scid kidneys show the
position of the germline (GL) band.1835 Davidson et al.
Previously, we and others reported an age-related accu-
mulation in lpr and gld mice of memory-like CD41 and
CD81 T cells with the capacity to secrete high levels of IL-4,
IL-10, IFN-g, and TNF-a (20–23). These cytokines, with
their well-established effects on B cell survival, proliferation
and differentiation (46–49), also may promote or enhance
B cell activation and contribute to the prolonged survival
and accumulation of plasma cells. Paradoxically, the accu-
mulation of memory cells in lpr and gld mice is associated
with defects in the capacity of T cells to proliferate and se-
crete IL-2 in vitro in response to a wide variety of mito-
gens, and superantigens (9, 50). Skewing of the T cell pop-
ulation towards memory cells and losses in mitogenic
responses and IL-2 production also occured in aging hu-
mans and normal 2–3 yr-old mice (51–53). In aged 1/1
mice, the memory T cell population had decreased expres-
sion of Fas and a defect in FasL-induced apoptosis (53).
Moreover, overexpression of Fas in CD2-Fas-transgenic
mice prevented the age-related accumulation of immuno-
deficient memory cells and also delayed thymic involution
(53). These observations suggest that T cell senescence is
associated with defective Fas-mediated signaling and this
may explain the apparent acceleration of immune senes-
cence in lpr and gld mice.
Our finding that the majority of the gld B cell tumors
were rejected by young 1/1, lpr and gld mice, implies that
the tumors were immunogenic for immunocompetent
mice and that rejection was not dependent on a functional
Fas-mediated apoptosis pathway. Parallel results were ob-
tained recently in mice made T cell-deficient by inactiva-
tion of both TCR-b and TCR-d genes. These mice nor-
mally develop IgM1 B cell lymphomas with low incidence
but tumor development was increased greatly if the mice
also were homozygous for lpr (45). In contrast to our sys-
tem, the tumors in the T cell–deficient lpr mice developed
rapidly and z60% of the mice had tumors by 7 mo of age
(45). Interestingly, lymphomagenesis in the lpr mice was
prevented if the mice had either TCR-a/b1 or TCR-g/
d1 T cells, implying that the tumor cells were immuno-
genic and that in young immunocompetent mice, each T
cell type was able to delete the tumor cells by a Fas-inde-
pendent pathway (45). This study and ours suggest that
chronic activation and enhanced survival of B cells together
with defective immune surveillance contribute to acceler-
ated lymphomagenesis in Fas–FasL-deficient mice.
A strong correlation between immunodeficiency and B
cell lymphomagenesis has been reported previously in hu-
mans and mice (40–42, 54, 55). In humans, immunodefi-
ciency resulting from treatment with immunosuppressive
drugs or secondary to infection with HIV greatly increases
the risk of B cell lymphoma development (41, 54, 55).
Similarly, patients with congenital or age-related immuno-
deficiencies, with a variety of autoimmune diseases, or with
angioblastic lymphoproliferative disorders have an in-
creased risk of developing B lineage tumors (41, 54, 56).
Like the gld tumors, human immunodeficiency-associated
lymphomas (IAL) also can retain their immunogenicity.
For example, IAL in organ transplant patients have been
reported to spontaneously regress when immunosuppres-
sive therapy is discontinued (41, 55).
Among mice, B lymphomas also develop with high fre-
quency in C57BL/6 mice infected with LP-BM5 murine
leukemia viruses which cause an acquired immunodefi-
ciency syndrome designated mouse AIDS (MAIDS; 57).
These aggressive IAL also can be propagated readily in scid
mice but are rejected by immunocompetent mice (58). In
another system involving C57BL/KaLwRij mice, a murine
model of multiple myeloma, plasmacytomagenesis corre-
lated strongly with an age-related T cell imunodeficiency
(59, 60). Because the gld B lymphomas share many of the
hallmarks of mouse and human IAL, we propose that they
represent a novel subset of IAL that develop as a result of
the complex and cumulative effects on the immune system
of defective Fas–FasL interactions. These effects may in-
clude chronic Ag-driven B cell activation, the ready avail-
ability of T cell help and growth factors, the loss of a major
elimination pathway for activated B cells, and an age-related
deficit in T cell–dependent immune surveillance.
The increased risk of B cell lymphomagenesis associated
with Fas and Fasl mutations is not restricted to mice. Re-
cently, a family was described in which two out of four
members with genomic FAS mutations and autoimmune
lymphoproliferative syndrome (ALPS) were diagnosed
with B cell lymphomas at 25 yr of age (61). In contrast,
none of the reported pediatric cases of ALPS with germline
FAS  mutations has a history of lymphoma (10–14). Al-
though the number of cases is small, the delayed develop-
ment of B cell tumors in the patients is consistent with our
findings in lpr and gld mice and implies that progression to
malignancy is dependent on the accumulation of additional
mutations in DNA. Other evidence for a possible associa-
tion between FAS mutations and B cell malignancy comes
from a recent study of patients with multiple myeloma in
which FAS mutations were detected in 10% of tumor-con-
taining bone marrow aspirates (62). Although we observed
nonlymphoid tumors only rarely in lpr and gld mice, two of
four ALPS patients described by Drappa et al. (14) devel-
oped nonlymphoid tumors in adulthood. It is not clear if
these tumors arose as a result of treatment with cytotoxic
drugs or infection with hepatitis virus or if FAS mutations
generally increase the risk of neoplasia.
Little is known about the sites or mechanisms of muta-
tion in IAL. Experimentally-induced plasmacytomas in
BALB/c mice consistently have c-Myc-activating t(12;15)
or t(6;15) translocations that are believed to be vital for the
transformation process (34, 36). In contrast, our primary or
passaged BALB-gld and C3H-gld plasmacytoid tumors,
which often evolved into plasmacytomas in scid passages,
had no evidence of c-Myc or Pvt1 rearrangement or amplifi-
cation suggesting that novel genetic mutations may substi-
tute for c-Myc dysregulation in these tumors. Similarly, c-Myc
translocations were not detected in the multiple myelomas
arising in the C57BL/KaLwRij mice or in the MAIDS B
cell lymphomas (58–60). In other experimental mouse
models of lymphomagenesis, murine leukemia viruses have
been found to induce neoplasms by integrating into the1836 B Cell Lymphomagenesis in gld Homozygous Mice
host DNA and mutating or transcriptionally activating
flanking genes (37). Our observation that a high proportion
of the gld tumors had one or more somatically acquired
proviral integrations that were stably transmitted in scid pas-
sages and cell lines, raises the possibility that insertional mu-
tagenesis may be a mechanism of transformation in gld IAL.
It is not known if interference with the Fas-mediated cell
death pathway only serves to increase the pool of targets for
transformation and to protect the tumors cells from Fas-
mediated apoptosis, or if mutations in Fas or Fasl cooperate
with other mutations. In this regard, it recently was re-
ported that the lpr mutation accelerated lymphomagenesis
in Em-L-myc transgenic mice but not in Em-Pim-1 trans-
genic mice (63,64), indicating that under some circum-
stances cooperation may occur.
Both BALB1/1 and C3H1/1 mice have been reported
to develop B lineage tumors, but these generally were not
detected until the mice were 2–3 yr of age (65, 66). In ad-
dition, the spontaneous neoplasms of 1/1 mice developed
with a much lower frequency, and were more morpholog-
ically diverse than the gld tumors (65, 66). Consistent with
the strain-related differences in tumor incidence observed
in the present study, the incidence of B cell tumors in the
BALB1/1 mice was significantly higher than in the C3H1/1
mice (66). The persistence in strain differences in tumor
susceptibility in the gld mice, suggests that the pro-onco-
genic effects of the FasL defect may complement, but not
override, preexisting tumor susceptibility factors. The tu-
mor accelerating effects of gld also are dependent on ho-
mozygosity as gld/1 mice showed no evidence of de-
creased lifespan or tumor development (data not shown).
This contrasts with our earlier studies where we observed
that SJL-lpr/1 mice developed B cell tumors more rapidly
and died earlier than SJL1/1 mice (67). It has yet to be de-
termined if this effect is lpr-dependent, strain-dependent, or
both.
The loss of B2201 DN T cells with advanced age in lpr
and gld mice has not been reported previously. The mecha-
nisms leading to the depletion of these cells are unknown
but may involve diminished production, or age-related ex-
haustion. Interestingly, CD81 T cells, which are the puta-
tive progenitors of B2201 T cells (16–19), often were
greatly increased in mice deficient in B2201 DN T cells.
One explanation for this observation is that only a subset of
CD81 T cells can differentiate into B2201 DN T cells and
that with time these either diminish in numbers or lose
their capacity to differentiate. The loss of B2201 DN T
cells and the development of B cell tumors appear to be co-
incidental events in the lpr and gld mice because many mice
with greatly diminished numbers of B2201 DN T cells
were tumor-free and not all tumor-bearing mice were de-
pleted of DN T cells.
In conclusion, we have shown that inactivation of the
Fas-mediated cell death pathway by mutation of Fas or Fasl
accelerates the development and greatly increases the inci-
dence of B cell lymphomas. It remains to be determined
how the complex immunologic sequelae that result from
these mutations contribute to the transformation process
and whether they may be manipulated for therapeutic pur-
poses.
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